February 4th 2025
The drug, a JAK inhibitor, met all primary and secondary endpoints in a phase 3 trial for adolescent CHE.
FDA Accepts Accord BioPharma's BLA for Proposed Ustekinumab Biosimilar DMB-3115
January 4th 2024The BLA submission for DMB-3115 is rooted in phase III multi-regional clinical trials focusing on plaque psoriasis patients. The results demonstrated a high similarity between DMB-3115 and ustekinumab in terms of quality, safety, and efficacy.